This study is for people up to 75 years old with certain types of leukemia (blood cancer) that have come back or haven't responded to standard treatments. Specifically, it's for acute myeloid leukemia (AML), T-cell leukemia, or B-cell leukemia where the cancer cells have a protein called CD70. You would receive a single infusion of special immune cells, called T cells, that have been modified to recognize and fight cancer cells with CD70. The study aims to find the safest dose of these modified T cells, called CD70.CAR T cells, by looking at any serious side effects within the first four weeks after treatment. This treatment uses your own immune system to target the cancer.

Study design

This is an interventional study with a planned enrollment of 12 participants. It involves different dose levels of the CD70.CAR T cell infusion.

What's involved

You will provide blood to create the special T cells for your treatment. These cells will be prepared and then given back to you as a single infusion.

Compensation

Not stated in the trial record.

Follow-up

The main safety outcome will be measured for four weeks after the infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.